Entero Therapeutics, Inc. (ENTO)
2025-06-30 | ||||
|---|---|---|---|---|
| Preferred stock dividends | 82,165 | |||
| Loss from discontinued operations net of tax | -323,340 | |||
| Research and development expenses | 10,631 | |||
| General and administrative expenses | 628,233 | |||
| Total operating expenses | 638,864 | |||
| Loss from operations | -638,864 | |||
| Interest income (expense), net | -36,067 | |||
| Total other expenses | -36,067 | |||
| Loss from continued operations | -674,931 | |||
| Net loss from continued operations | -674,931 | |||
| Net loss | -998,271 | |||
| Net loss applicable to common shareholders | -1,080,436 | |||
| Earnings per share, basic | -0.21 | |||
| Earnings per share, diluted | -0.21 | |||
| Weighted average number of shares outstanding, basic | 4,765,004 | |||
| Weighted average number of shares outstanding, diluted | 4,765,004 | |||